Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
Condition(s) studied
Investigational drug(s) / intervention(s)
R2R01: Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.
Terlipressin: In the US, terlipressin is supplied as a sterile, preservative-free, lyophilized, white-to- off-white powder for intravenous (IV) administration. Each vial contains 0.85 mg Terlivaz, equivalent to 1 mg terlipressin acetate, and 10.0 mg mannitol. Terlivaz requires reconstituting in saline (5mL). In the EU, terlipressin is supplied in a clear glass vial with 5 ml of injection solution, containing 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin.
Study summary
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
Eligibility
Primary outcome measure(s)
- Safety Evaluation Criteria - Treatment Emergent Adverse Events (TEAEs) — From first dose of study drug to 30 days post last dose
Safety and tolerability will be assessed by occurrence of TEAEs. Outcome will be reported as the count of participant experiencing TEAEs. - Safety Evaluation Criteria - Change in Weight — Change from screening through Day 30
Safety and tolerability will be assessed by change in body weight - Safety Evaluation Criteria - Vital Signs - Respiration Rate — Change from screening through Day 30
Safety and tolerability will be assessed by change in respiration rate - Safety Evaluation Criteria - Vital Signs - Body Temperature — Change from screening through Day 30
Safety and tolerability will be assessed by change in body temperature - Safety Evaluation Criteria - Vital Signs - Continuous pulse oximetry (SpO2) — Change from baseline through Day 30
Safety and tolerability will be assessed by change in SpO2 - Safety Evaluation Criteria - Vital Signs - Systolic Blood Pressure (SBP) — Change from screening through Day 30
Safety and tolerability will be assessed by change in SBP - Safety Evaluation Criteria - Vital Signs - Diastolic Blood pressure (DBP) — Change from screening through Day 30
Safety and tolerability will be assessed by change in DBP - Safety Evaluation Criteria - Vital Signs - Heart Rate (HR) — Change from screening through Day 30
Safety and tolerability will be assessed by change in Heart Rate (HR) - Safety Evaluation Criteria - ECGs - PR interval — Change from screening to Day 14 or hospital discharge
Safety and tolerability will be assessed by occurrence of ECGs - Safety Evaluation Criteria - ECGs - RR interval — Change from screening to Day 14 or hospital discharge
Safety and tolerability will be assessed by occurrence of ECGs - Safety Evaluation Criteria - ECGs - QRS duration — Change from screening to Day 14 or hospital discharge
Safety and tolerability will be assessed by occurrence of ECGs - Safety Evaluation Criteria - ECGs - QT interval — Change from screening to Day 14 or hospital discharge
Safety and tolerability will be assessed by occurrence of ECGs - Safety Evaluation Criteria - ECGs - QTcF interval — Change from screening to Day 14 or hospital discharge
Safety and tolerability will be assessed by occurrence of ECGs - Safety Evaluation Criteria - ECGs - QTcB interval — Change from screening to Day 14 or hospital discharge
Safety and tolerability will be assessed by occurrence of ECGs - The incidence of Responders — 90 days
The incidence of Responders (Established HRS reversal defined as patients with a Full or Partial HRS response (based on SCr/AKI stage) AND are alive without Renal Replacement Therapy (RRT) for at least 30 days after the first dose of study medication), evaluated separately as two different outcome groups and combined. In case of recurrence and retreatment during the first 30 days, the second treatment period will be evaluated for response
Trial sites (7)
| Facility | City | Region | Status |
|---|---|---|---|
| California Pacific Medical Center | San Francisco | California | Not Yet Recruiting |
| Piedmont Healthcare, Inc | Atlanta | Georgia | Recruiting |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | Not Yet Recruiting |
| Mayo Clinic | Rochester | Minnesota | Recruiting |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | Recruiting |
| Vanderbilt University Medical Center | Nashville | Tennessee | Recruiting |
| Baylor Scott and White All Saints Medical Center | Fort Worth | Texas | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05875948 on ClinicalTrials.gov ↗ ← All trials in the USA